| Literature DB >> 16214092 |
Francesco Puppo1, Giuseppe Murdaca, Massimo Ghio, Francesco Indiveri.
Abstract
This article reviews the role of emerging biologic drugs for the treatment of rheumatoid arthritis (RA). Besides anti-tumor necrosis factor (TNF)-alpha and anti-interleukin (IL)-1 agents (Infliximab, Adalimumab, Etanercept and Anakinra) whose clinical efficacy is now established, new drugs have been proposed for the therapy of rheumatoid arthritis patients not responding to conventional treatments. These approaches include the blockade of B-cell activity with anti-CD20 monoclonal antibody (Rituximab) and the inhibition of T-cell activation with fusion protein CTLA4Ig. Moreover, promising results have been obtained in animal models utilizing suppressors of cytokine signaling (SOCS) and dominant-negative TNF variants to inactivate TNF signaling.Entities:
Mesh：
Substances：
Year: 2005 PMID： 16214092 DOI： 10.1016/j.autrev.2005.04.016
Source DB: PubMed Journal: Autoimmun Rev ISSN： 1568-9972 Impact factor: 9.754